BeaconEquity.com – InterMune Inc. (ITMN) Shows Positive Trial Results for Hepatitis C Treatment
InterMune Inc. (Nasdaq: ITMN), a biotechnology company, focuses on the development and commercialization of therapies in pulmonology and hepatology. The company offers Actimmune for the treatment of chronic granulomatous disease and severe, malignant oste
(EMAILWIRE.COM, April 07, 2008 ) BeaconEquity.com announces the publication of ‘InterMune Inc. (ITMN) Shows Positive Trial Results for Hepatitis C Treatment’
Investors can view all of the investment articles for free by visiting:
http://www.BeaconEquity.com - Click on News and Commentary
InterMune Inc. (ITMN) Shows Positive Trial Results for Hepatitis C Treatment
InterMune Inc. (Nasdaq: ITMN), a biotechnology company, focuses on the development and commercialization of therapies in pulmonology and hepatology. The company offers Actimmune for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis in the United States.
InterMune also develops Pirfenidone, which is in phase III clinical status for the treatment of idiopathic pulmonary fibrosis, interferon gamma products that are in a preclinical stage, and the Protease Inhibitor program, which is in a phase I clinical stage for the treatment of hepatitis C virus infections.
InterMune recently announced positive top-line results of an early-stage trial for ITMN-191, a hepatitis C treatment candidate. InterMune shares rose as news was released that the drug, given in gelatin capsules, delivered results similar to other hepatitis C drugs and exhibited flexibility in dosing.
To read the entire article visit http://www.BeaconEquity.com – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Investors can view all of the investment articles for free by visiting:
http://www.BeaconEquity.com - Click on News and Commentary
InterMune Inc. (ITMN) Shows Positive Trial Results for Hepatitis C Treatment
InterMune Inc. (Nasdaq: ITMN), a biotechnology company, focuses on the development and commercialization of therapies in pulmonology and hepatology. The company offers Actimmune for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis in the United States.
InterMune also develops Pirfenidone, which is in phase III clinical status for the treatment of idiopathic pulmonary fibrosis, interferon gamma products that are in a preclinical stage, and the Protease Inhibitor program, which is in a phase I clinical stage for the treatment of hepatitis C virus infections.
InterMune recently announced positive top-line results of an early-stage trial for ITMN-191, a hepatitis C treatment candidate. InterMune shares rose as news was released that the drug, given in gelatin capsules, delivered results similar to other hepatitis C drugs and exhibited flexibility in dosing.
To read the entire article visit http://www.BeaconEquity.com – Click on News and Commentary
Join the fastest growing investor community at:
http://www.stockhideout.com
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting: http://www.BeaconEquity.com
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.BeaconEquity.com
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Press Release Keywords:
micro cap, investing, stock market, intermune inc, pulmonology, hepatology, actimmune, chronic disease, disease treatment, hepatitis c, viral infection, fighting infections,
micro cap, investing, stock market, intermune inc, pulmonology, hepatology, actimmune, chronic disease, disease treatment, hepatitis c, viral infection, fighting infections,
|
How to buy Penny Stocks
Learn the Skills, Make the Trades, Earn a Fortune! 100% Free to try. Chartpoppers.com Stop Being Fooled By "Penny Stock Picks" Subscribe To The #1 Rated MicroCap Stock Newsletter. MicroCapster.com Analyst Penny Stock Picks Visit StockSource.us for explosive stock picks, free stock research and trading tools www.StockSource.us Your text Ads here! Ads are only $575 per month. Ads are placed same day. Contac Us Emailwire.com/contact.php |